ENLIVEN THERAPEUTICS INC. - COMMON STOCK

27,53

04-октября-24 14:59:59

15 мин. задержка

Акции

+2,02

+7,92%

Сегодняшний диапазон

25,48 - 27,62

ISIN

N/A

Источник

NASDAQ

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

28 сен 2024 08:35:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

18 сен 2024 15:05:07 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics to Present at Two Upcoming Investor Conferences

29 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

14 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

11 апр 2024 06:55:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

09 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

28 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.